logo-loader
viewOpen Orphan PLC

Open Orphan PLC - integration on track one week on from IPO

Cathal Friel, chief executive of Open Orphan PLC (ORPH), caught up with Proactive London's Andrew Scott a week on from its re-admission to AIM.

Friel reversed Open Orphan into Venn Life Sciences in a £5.7mln all-paper deal and will be targeting what he describes as a fragmented orphan drug services market in Europe.

Quick facts: Open Orphan PLC

Price: 6.58 GBX

AIM:ORPH
Market: AIM
Market Cap: £29.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Open Orphan confirms hVIVO deal is done

Cathal Friel, CEO of Open Orphan announces that the hVIVO deal is finally in the bag and tells Proactive London what the timeline for shareholders now looks like. News here on the Genomic Database and how Friel expects hVIVO to make a profit. Confirmation too on the slight musical chairs within...

1 week ago

RNS

Holding(s) in Company

7 hours, 16 minutes ago

Holding(s) in Company

7 hours, 26 minutes ago

Holding(s) in Company

1 day, 3 hours ago

Euronext Growth Dublin Notice

2 days, 9 hours ago

Offer Wholly Unconditional

5 days, 10 hours ago

2 min read